Listed

Adaptimmune Therapeutics PLC: Form 10-Q for the period ended Sep 30, 2017

Filed with the SEC on Nov 2, 2017 and accepted by EDGAR at Nov 2, 2017, 10:46 ET.

Share

Sections

The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.

Figures reported in this filing

Standardized line items from the XBRL in this filing, for the period ended 2017-09-30. Comparative periods it repeats are left out.

Figures reported in this filing
Line itemPeriodValueXBRL concept
Research and development3 months2017-07-01 to 2017-09-30$24.0mus-gaap:ResearchAndDevelopmentExpense
Research and development9 months2017-01-01 to 2017-09-30$62.2mus-gaap:ResearchAndDevelopmentExpense
Operating income3 months2017-07-01 to 2017-09-30−$5.0mus-gaap:OperatingIncomeLoss
Operating income9 months2017-01-01 to 2017-09-30−$51.0mus-gaap:OperatingIncomeLoss
Interest expense3 months2017-07-01 to 2017-09-30$8.0kus-gaap:InterestExpense
Interest expense9 months2017-01-01 to 2017-09-30$14.0kus-gaap:InterestExpense
Income tax3 months2017-07-01 to 2017-09-30$225.0kus-gaap:IncomeTaxExpenseBenefit
Income tax9 months2017-01-01 to 2017-09-30$621.0kus-gaap:IncomeTaxExpenseBenefit
Net income3 months2017-07-01 to 2017-09-30−$878.0kus-gaap:NetIncomeLoss
Net income9 months2017-01-01 to 2017-09-30−$42.9mus-gaap:NetIncomeLoss
Diluted EPS3 months2017-07-01 to 2017-09-30$0.00us-gaap:EarningsPerShareBasicAndDiluted
Operating cash flow9 months2017-01-01 to 2017-09-30−$33.0mus-gaap:NetCashProvidedByUsedInOperatingActivities
Capital expenditure9 months2017-01-01 to 2017-09-30$22.8mus-gaap:PaymentsToAcquirePropertyPlantAndEquipment
Cash and equivalentsAt period end2017-09-30$145.3mus-gaap:CashAndCashEquivalentsAtCarryingValue
Current assetsAt period end2017-09-30$253.9mus-gaap:AssetsCurrent
Total assetsAt period end2017-09-30$301.4mus-gaap:Assets
Current liabilitiesAt period end2017-09-30$68.6mus-gaap:LiabilitiesCurrent
Total liabilitiesAt period end2017-09-30$72.4mus-gaap:Liabilities
Shareholders' equityAt period end2017-09-30$229.0mus-gaap:StockholdersEquity

Source: SEC EDGAR, the filing index for accession 0001104659-17-065442. Last ingested by Listed: Oct 24, 2026, 15:14 ET. Listed shows no prices and gives no investment advice.